Results 81 to 90 of about 31,541 (206)

Advances and Challenges in Machine Learning‐based Image Analysis for Monitoring and Predicting Organic Crystal Formation

Aggregate, Volume 7, Issue 6, June 2026.
This review explores the application of machine learning‐based image analysis technology in four major organic crystallization tasks, providing a reference for subsequent research in the corresponding fields. ABSTRACT Manual crystallization experiments have always been challenging, requiring extensive process development expertise and often resulting ...
Tianqi Ma, Yating Qu, Chenxian Guan, Hang Yin, Wenmian Yang, Shing Fung Chow, Henry Hoi Yee Tong, Defang Ouyang, Zhuyifan Ye   +8 more
wiley   +1 more source

Targeting Middle East Respiratory Syndrome Coronavirus Spike Fusion Machinery With Antiviral Peptides: In Silico Exploration of the Heptad Repeat 2 Domain

MicrobiologyOpen, Volume 15, Issue 3, June 2026.
Griffithsin, Brevinin‐2, and CCL20 were identified as potent MERS‐CoV fusion inhibitor candidates targeting the HR2 domain through integrated molecular docking, MD simulations, and MM/PBSA analyses. These peptides demonstrated superior binding stability and favorable safety profiles compared to the standard inhibitor, supporting their potential as ...
Nasser Alotaiq, Doni Dermawan, Samir Chtita   +2 more
wiley   +1 more source

Structural multiplicity in a solvated hydrate of the antiretroviral protease inhibitor Lopinavir

Acta Crystallographica Section E: Crystallographic Communications
Lopinavir is a potent protease inhibitor that is used as a first-line pharmaceutical drug for the treatment of HIV. The multi-component solvated Lopinavir crystal, systematic name (2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6 ...
Tebogo M. L. Mokoto, Andreas Lemmerer, Yasien Sayed, Mark G. Smith   +3 more
doaj   +1 more source

Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. [PDF]

, 2009
Contains fulltext : 79592.pdf (Publisher’s version ) (Open Access)Thirty-four patients treated concomitantly with lopinavir/ritonavir and rifampicin were evaluated.
van Crevel, Reinout, Burger, David M., Boeree, M.J., Gras, Luuk, Nijland, H.M.J., Brinkman, K., Prins, J.M., Crevel, R. van, Aarnoutse, Rob E., Juttmann, J.R., L'homme, R.F.A., Juttmann, Job R., Burger, D.M., Nijland, Hanneke M. J., Boeree, Martin, Prins, Jan M., Aarnoutse, R.E., Brinkman, Kees, Gras, L., L'homme, Rafaëlla Fa   +19 more
core   +1 more source

The impact of accumulating immune adaptation in circulating strains of HIV‐1

HIV Medicine, Volume 27, Issue 6, Page 918-934, June 2026.
Abstract Background Mutations in human immunodeficiency virus type 1 (HIV‐1) enable the virus to evade recognition and killing by human leucocyte antigen (HLA)‐restricted T cells. These viral adaptations are specific to the HLA type of individuals and are therefore evident as HLA allele‐HIV sequence associations at the population level. Most studies of
Marwah Al‐kaabi, Alison Castley, Pooja Deshpande, Abha Chopra, David Nolan, Simon Mallal, Mina John, Silvana Gaudieri   +7 more
wiley   +1 more source

Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.

PLoS ONE, 2014
BackgroundRifampicin and protease inhibitors are difficult to use concomitantly in patients with HIV-associated tuberculosis because of drug-drug interactions. Rifabutin has been proposed as an alternative rifamycin, but there is concern that the current
Nguyen Thi Ngoc Lan, Nguyen Thi Nguyet Thu, Aurélie Barrail-Tran, Nguyen Hong Duc, Nguyen Ngoc Lan, Didier Laureillard, Truong Thi Xuan Lien, Laurence Borand, Catherine Quillet, Catherine Connolly, Dominique Lagarde, Alexander Pym, Christian Lienhardt, Nguyen Huy Dung, Anne-Marie Taburet, Anthony D Harries   +15 more
doaj   +1 more source

Arbidol Monotherapy is Superior to Lopinavir/ritonavir in Treating COVID-19 [PDF]

, 2020
Lopinavir/ritonavir and arbidol have been previously used to treat acute respiratory syndrome- coronavirus 2 (SARS-CoV-2) replication in clinical practice; nevertheless, their effectiveness remains controversial. In this study, we evaluated the antiviral
Lu, Zhaohui, Jianchun, Xue, Yuan, Chen, Cong, Zhu, Zhen, Xu, Tianmin, Zha, Tao, Yang, Gang, Lu, Jianchun   +8 more
core   +1 more source

Accelerating Generic Long‐Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to Access

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1195-1204, May 2026.
The global HIV response aims for widespread availability of affordable, quality‐assured long‐acting antiretroviral (LA ARV) drugs to achieve sustained epidemic control, particularly in low‐ and middle‐income countries. This report summarizes key discussion points, findings, and outcomes from an international workshop on generic LA ARVs, held in ...
Usman Arshad, Lobna Gaayeb, Henry Pertinez, Rajith K. R. Rajoli, Melynda Watkins, Parag Nimbolkar, Simone Perazzolo, Bharat Pagi, Annemarie Wensing, Saye Khoo, Marta Boffito, René Holm, Zack Panos, Imelda Mahaka, Francois Venter, Benny Kottiri, Keith W. Crawford, Rodney J. Y. Ho, Polly Clayden, Paul Domanico, Kimberly Struble, Andrew Owen, Charles Flexner   +22 more
wiley   +1 more source

Viral Mechanisms and Drug Influences on Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) Pathway in Human Coronaviruses Infection: A Systematic Review

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aim Janus kinases/signal transducers and activators of transcription (JAK/STAT) pathway is crucial for various stages of immunity, from innate to adaptive responses. Type 1 IFNs activate JAK/STAT pathway by binding to receptors on JAK, phosphorylating STAT and upregulating interferon‐stimulated genes (ISGs) leading to cytokines ...
Esimebia Adjovi Amegashie, Ruth Oyawole Sikeola, Caleb Koranteng Kwayisi‐Darkwah, Gabriel Atampugbire, Emmanuel Ayitey Tagoe, Elijah Paintsil, Kwasi Torpey, Osbourne Quaye   +7 more
wiley   +1 more source

The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial

Trials, 2020
Objectives To determine if lopinavir/ritonavir +/- hydroxychloroquine will reduce the proportion of participants who survive without requiring ventilatory support, 15 days after enrolment, in adult participants with non-critically ill SARS-CoV-2 ...
Justin T. Denholm, Joshua Davis, David Paterson, Jason Roberts, Susan Morpeth, Thomas Snelling, Dominica Zentner, Megan Rees, Matthew O’Sullivan, David Price, Asha Bowen, Steven Y. C. Tong, for the ASCOT Investigator Group   +12 more
doaj   +1 more source